anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
TP53 pathogenic variants cause Li-Fraumeni syndrome (LFS), with some variants causing an attenuated phenotype. Herein, we describe the clinical phenotype and genetic characteristics of carriers of NM_000546.6 (TP53): c.541C > T, (p.Arg181Cys) treated at Hadassah Medical Center. We retrospectively examined our genetic databases to identify all carriers of TP53 p.Arg181Cys. We reached out to carriers and their relatives and collected clinical and demographic data, lifestyle factors, carcinogenic exposures as well as additional blood samples for genetic testing and whole exome sequencing. Between 2005 and 2022 a total of 2875 cancer patients underwent genetic testing using genetic panels, whole exome sequencing or targeted TP53 assays. A total of 30 cancer patients, all of Arab-Muslim descent, were found to be carriers of TP53 p.Arg181Cys, the majority from Jerusalem and Hebron, two of which were homozygous for the variant. Carriers were from 24 distinct families of them, 15 families (62.5%) met updated Chompret criteria for LFS. Median age of diagnosis was 35 years-old (range 1-69) with cancers characteristic of LFS (16 Breast cancer; 6 primary CNS tumors; 3 sarcomas) including 4 children with choroid plexus carcinoma, medulloblastoma, or glioblastoma. A total of 21 healthy carriers of TP53 p.Arg181Cys were identified at a median age of 39 years-old (range 2-54)-19 relatives and 2 additional pediatric non-cancer patients, in which the finding was incidental. We report a shared haplotype of 350kb among carriers, limited co-morbidities and low BMI in both cancer patients and healthy carriers. There were no demographic factors or carcinogenic exposures unique to carriers who developed malignancy. Upon exome analysis no other known pathogenic variants in cancer predisposing genes were identified. TP53 p.Arg181Cys is a founder pathogenic variant predominant to the Arab-Muslim population in Jerusalem and Hebron, causing attenuated-LFS. We suggest strict surveillance in established carriers and encourage referral to genetic testing for all cancer patients of Arab-Muslim descent in this region with LFS-associated malignancies as well as family members of established carriers.
PURPOSE:To obtain the titled composition having high dissolution rate of tritoqualine in water, by blending a compound selected from crystalline cellulose, cyclodextrin, light silicic anhydride, etc., with tritoqualine and grinding. CONSTITUTION:The titled composition containing 1pt.wt. tritoqualine shown by formula I and 1-10pts.wt. (preferably 2-9pts.wt.) one or more compounds selected from crystalline cellulose, cyclodextrin, methylated cyclodextrin, light silicic anhydride, synthetic aluminum silicate and magnesium metasilicate. The two components are blended and ground by using a vibration mill and a ball mill preferably until the ground materials are made into amorphous so that elution properties of tritoqualine are excellently improved and long-acting supersaturation phenomena can be exhibited. A dose of tritoqualine is 10-2,000mg per adult daily.
The invention provides a sustained release preparation of levamlodipine besylate tablets or salts thereof. The sustained release preparation comprises a quick release phase and a sustained release phase, wherein the quick release phase and the sustained release phase respectively independent or the quick release phase wraps the sustained release phase; the quick release phase contains part of active ingredients of the medicine; the sustained release phase contains the rest part of the active ingredients of the medicine; the active ingredients of the medicine comprise the levamlodipine besylate tablets or the salts thereof, and are counted as 2.5 mg-20 mg as the levamlodipine besylate tablets, and in a release medium which meets a sink condition, more than 90% by weight of the active ingredients of the medicine are released in a release period of 6-14 hours. The sustained release preparation cannot comprise the quick release phase. The invention further provides a related preparation method. The sustained release preparation of levamlodipine besylate tablets or salts thereof is convenient to use, high in curative effect, good in taking compliance and less in adverse reaction, and can take effect quickly. Stable and effective blood concentration can be maintained for a long time. The sustained release preparation is skillful in design and simple in structure, has good stability and is suitable for large-scale popularization and application.
EIDD-2801 (also known as MK-4482, molnupiravir). Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.
Management of diabetes is a complex process involving the conduct of daily self-care activities, problem-solving, and decision-making. Even in the most supportive environment, adherence to the daily regimen is difficult. Adherence is typically lowest among adolescents, who are taking increasing amounts of responsibility for their diabetes management while still maturing cognitively and socially. This pilot study will investigate the feasibility and effectiveness of a personal diabetes trainer in promoting adherence among early adolescents. A sample of 120 youth ages 11 to 16 will be randomized to informational control or a diabetes personal trainer intervention. Measures of adherence, adjustment, conflict, attitudes, and parental involvement will be obtained at baseline, two months, six months, and one year following. Measures of glycemic control will be abstracted from the medical records.
Sepsis is a life-threatening syndrome and the most common cause of death nowadays. This syndrome develops as a result of the dysregulated host response to an infectious insult. As such the mainstay of treatment is the early administration of antimicrobials leading to early eradication of the offending pathogen. However, in this statement the key-feature is the definition of what "early" means. Using the retrospective analysis of data associating final outcome from septic shock with the delay in start of antimicrobials from the start of vasopressors in 2713 patients with septic shock, it was found that 79.1% of patients in which this delay was less than one hour survived. Every further hour of delay in start of antibiotics led to 7.6% increase of the risk for unfavorable outcome. These findings were later confirmed from two other analyses. These findings generate two thoughts: a) the above results are based on early recognition of hospital-acquired sepsis that was achievable only because these studies were done in an Intensive Care Unit (ICU) environment in patients under close monitoring. However, early sepsis recognition for a newly admitted patient remains an unmet need; b) all the above results are coming from patients with septic shock where diagnosis had already been established since patients were already on vasopressors.

It is reasonable to hypothesize that if sepsis had been recognized even earlier final outcome would have been even better. Sanmina have developed a non-invasive technique for the measurement of endothelial released nitric oxide (NO) through customized pulse photoplethysmography (PPG). Since NO is released by the vascular endothelium early in the pathogenesis of sepsis it is reasonable to hypothesize that PPG is a technique that can early inform on the risk for a patient with suspicion of an infection to develop sepsis. The time of measurement is less than two minutes. Preliminary data show that the reading of a healthy subject of eight consecutive minutes cannot trace any increase of NO; in sepsis a peak of more than 200 units is shown within the first 40 seconds of measurement.

The development of PPG as a tool for the early diagnosis of sepsis requires a two-stage approach. The first stage is based on the association of PPG readings with the change of the SOFA (sequential organ failure assessment) score and vital signs to define if among patients who eventually develop sepsis, PPG changes will be produced earlier than changes of SOFA scores and of vital signs.
Repetitive transcranial magnetic stimulation (rTMS) is an established technology as therapy for treatment-resistant depression. The approved method for treatment is 10Hz stimulation for 40 minutes over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been very successful in real-world situations. The limitations of this approach include the duration of the treatment (approximately 40 minutes per treatment session over 4-6 weeks). Recently, researchers have aggressively pursued modifying the treatment parameters to reduce treatment times with some preliminary success. In a recent study, the investigators applied this accelerated paradigm in individuals with treatment-resistant depression (TRD), which showed a significant antidepressant effect (90% remission rate). Additionally, 3 participants from this study carried a bipolar TRD diagnosis and responded at minimum, equally as well, with no adverse events experienced or manic/hypomanic conversion observed during the treatment series. This study intends to further modify the parameters to create a more rapid form of this treatment for bipolar TRD, and look at the change in clinical measures and neuroimaging biomarkers.
Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells after 28 days.
NEW MATERIAL:A compound shown by the formula I (R1 and R2 are H, halo gen, lower alkyl, lower alkoxyl, etc.; R3 and R4 H, halogen, etc.; X is O, or S). EXAMPLE:1-[1-(2-(5-Chlorothiophen)oxyl)phynyl]vinyl]1-H-imidaz-ole. USE:An antifungal agent. PREPARATION:A compound shown by the formula II is reacted with a com pound shown by the formula III (Y is Cl, or Br) to give a reaction product, and the reaction product is isolated by a conventional procedure to give a compound shown by the formula I. For example, the aimed compound is obtained by converting the hydroxyl group of the compound shown by the formula II into potassium salt or sodium salt, and reacting the resultant com pound with the compound shown by the formula III by the use of pyridine, acetonitrile, etc., as a solvent.
OBJECTIVES: Childhood obesity has become a global threat due to its serious negative consequences. We aimed to determine the patterns of metabolic syndrome and cardio-metabolic risk factors in Turkish children with obesity.
METHODS: We examined 169 schoolchildren with obesity in April and May 2019 in Samsun, Turkey. After clinical evaluation and anthropometric measurements, fasting blood samples were collected to measure total cholesterol, low and high-density lipoprotein, fasting blood glucose, triglycerides, and insulin levels.
RESULTS: The proportion of those who met the metabolic syndrome criteria in boys was 14.3%, but it was twice as high in girls (28.2%). The most prevalent component of cardio-metabolic risk factor was increased waist circumference (96.4%) followed by a high homeostasis model assessment insulin resistance index (74.6%) and high blood pressure (29.0%). While the average high-density lipoprotein was higher in boys than in girls, on the contrary, insulin, HbA1c, and homeostasis model assessment insulin resistance concentrations were higher in girls. The prevalence of dyslipidemia was also higher in girls (67.1%) than in boys (47.6%), as were all impaired metabolic syndrome components.
CONCLUSIONS: One in five children with obesity was at risk of metabolic syndrome. For early intervention and prevention, children with obesity should be monitored in terms of cardio-metabolic risk factors, but obese girls are more prioritized.
A dose escalation schema will be employed. Three to six patients will be treated at each of the following dose levels with EBV-Specific CTLs and CD45 Mab: Dose Level I: 2 x 10\^7 cells/m2. Dose Level II: 5 x 10\^7 cells/m2. Dose Level III: 1 x 10\^8 cells/m2. Dose escalation decisions will be made after review of the data from the current dose level. There will be no intra-patient escalation. An additional 6-10 patients with measurable disease will be treated at the recommended phase II dose to expand the experience at this dose level.
In Part 4B cohort expansion, subjects will be assigned to expansion cohorts at a selected dose of trametinib in combination with panitumumab. Enrollment in expansion cohorts will be initiated once dose escalation for the trametinib /panitumumab combination has been completed. Subjects with advanced/metastatic CRC with either a BRAF-mutation (Cohort 1E) or who developed secondary resistance to prior anti-EGFR therapy (Cohort 2E).
Depressive symptoms and inflammatory markers have both been proposed as measures that indicate/precede coronary artery disease (CAD). However, no controlled research study has tested the impact of these two candidate CAD risk factors within the same design to see the directionality of their influence. This study will explore if simvastatin reduces depressive symptoms and if sertraline reduces C-Reactive protein (CRP). Additionally, the recruitment process will help determine the feasibility of a larger trial, powered for significance testing. Three hundred and seventy-five participants will be consented and screened for this study. We expect forty-two otherwise healthy outpatients to have both elevated symptoms and high CRP levels, and be willing to be randomly assigned to sertraline, an antidepressant, simvastatin, a drug with anti-inflammatory properties, or a placebo for 8 weeks. Depressive symptoms and inflammatory indicators will be assessed before treatment (screening and baseline), mid-treatment (after 4 weeks), post-treatment (after 8 weeks), and a follow-up visit (after 12 weeks), using blood tests and depression interviews. We expect that both inflammation and depressive symptoms may be reduced by both medications, but the number of subjects needed to test this hypothesis is not yet known. Hence, this pilot study will be conducted. Knowledge about the inter-dependency of these two CAD risk factors allows the most promising future observational/intervention studies to be designed and conducted.
Obstructive sleep apnea(OSA) is characterized by multiple episodes of upper airway collapse during sleep and considered as a major health issue worldwide due to comorbidity with obesity, hypertension, diabetes and more advanced cardiovascular diseases. The noisy sounds of snoring caused by OSA bother bed partner sleepless and lead to long-term health problems. Most patients do not tolerate nasal continuous positive airway pressure device, which is the gold standard treatment of OSA. Press needle is one kind of acupuncture which possesses more safety and convenient, few complications and prolonged period of treatment time compared to conventional acupuncture. To date, there is no study to evaluate the effects of press needle in treating OSA. The investigators hypothesize that press needle is effective with high acceptability among OSA patients.
Patients receive paclitaxel and carboplatin as in arm I. Patients also receive placebo PO once daily on days -2 to 2.
In the control group. pre- and postextraction CBCT data sets of 14 patients with 21 extracted teeth were collected. 11 maxillary single rooted teeth and 10 single rooted teeth in the mandible (13 incisors, 2 canines and 6 premolars) were extracted and left for spontaneous healing.
The expected signs and symptoms with overdosage of SEREVENT DISKUS are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms of beta-adrenergic stimulation (e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis). Overdosage with SEREVENT DISKUS can lead to clinically significant prolongation of the QTc interval, which can produce ventricular arrhythmias.

As with all inhaled sympathomimetic medicines, cardiac arrest and even death may be associated with an overdose of SEREVENT DISKUS.

Treatment consists of discontinuation of SEREVENT DISKUS together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of SEREVENT DISKUS. Cardiac monitoring is recommended in cases of overdosage.
FIELD: medicine. ^ SUBSTANCE: invention concerns a solid oral dosage form composition containing therapeutically effective amount of aliskiren or its pharmaceutically acceptable salt in amount exceeding 46 wt %. The oral dosage form represents a tablet or a film-coated tablet. Aliskiren tablet is made by wet granulation with using mixed organic solvents or organic binding solutions. ^ EFFECT: elimination of aqueous granulation provides high stability of the dosage form of aliskiren and prolonged shelf-life. ^ 18 cl, 2 ex
The invention provides a dendrobium officinale extract. In the extract, the content of dendrobium officinale polysaccharides is 70.0-90.0%, and the content of general flavones is 0.5-1.0%. The dendrobium officinale extract is capable of being used for preparing medicines or health products for preventing and treating embolic cardiovascular and cerebrovascular diseases and renal diabetes. The invention further provides a preparation method of the extract. The preparation method specifically comprises the four steps of organic solvent degreasing, flash extraction after ethanol solution soaking, Sevage reagent deproteinization and active carbon decolouration. The preparation method is capable of protecting the dendrobium officinale effective ingredient not to be thermally broken and furthest effectively extracting the dendrobium officinale polysaccharides and the flavones simultaneously, low in solvent dosage, short in extraction time, and capable of improving product quality and reducing production cost.
A new class of biologically-active copolymers is provided capable of affecting biological systems in many different ways. The biologically-active copolymers of the present invention also have a wide variety of effects on individual cells. The biologically-active copolymers are also effective against certain microorganisms. The biologically active copolymers of the present invention can be administered to animals to provide specific effects on certain microorganisms that reside in the gut of the animal. A preferred use is administering the biologically active copolymers of the present invention to poultry to reduce the number of Salmonella in the poultry gut. Another preferred use is treatment of surfaces to interfere with the adhesion of microorganisms to the surfaces.
PROBLEM TO BE SOLVED: To find out a new plant extract having testosterone 5α-reductase inhibiting action and/or androgen receptor binding inhibiting action and provide a new antiandrogen agent, a hair growing cosmetic, etc., for treatment and prevention suitable for symptoms such as male pattern baldness, hirsutism, seborrhea, etc., based on increase of androgenic hormone stimulation. SOLUTION: The testosteron 5α-reductase inhibitor, the androgen receptor binding inhibitor and the antiandrogen agent having testosteron 5α-reductase inhibiting action and/or androgen receptor-binding inhibiting action are each obtained by extracting one or two or more kinds of plants selected from a group consisting of Taxus chinensis(Pilg.)Rehd., Canarium pimela Koenig, Heteropanax fragrans(Roxb.)Seem. and Andrographis paniculata(Burm.f.)Nees with water or an aqueous solvent such as a hydrophilic organic solvent or mixture solution of the hydrophilic organic solvent with water. The hair growing cosmetic, prostatic hypertrophy suppressing agent and health auxiliary agent are each obtained by using the testosteron 5α-reductase inhibitor and/or the androgen receptor binding inhibitor.
The "Run, jump \& fun" intervention consists of four 30 minutes sessions per week for one school year. Activities are mostly conducted as whole class activities. Head of schools and teachers/school pedagogues are involved in an initial intervention establishing process, guided by Active School personnel. The aim is to create a local plan for the intervention tailored to the particular school. Examples are "movement band", structured activities during recess with older students (13-15 years olds), etc. Activities are created to be fun, motivating and with moderate to high intensity PA.
Constipation is a prevalent gastrointestinal disorder that affects people globally, decreasing their quality of life and life expectancy. Individuals with schizophrenia often suffer from constipation, which could be a result of the illness itself or the side effects of psychotropic medications. However, little research has been conducted on factors contributing to constipation in individuals with schizophrenia. To address this issue, we conducted a survey using self-administered questionnaires and medical records to identify factors associated with constipation in psychiatric outpatients. This study included 399 patients with schizophrenia, resulting in a high prevalence of constipation (43.4%). The analysis suggested that female gender, the doses of antiparkinsonian medications, and benzodiazepine sleeping pills may be associated with constipation.
Participants will complete one phone session including education about the treatment followed by four online sessions of a writing and thinking intervention across a one month time period. Each session is separated by 1 week.
Systems, methods and computer-readable media are provided for determining a premium for a proposed insurance coverage. In various embodiments, a plurality of context variables can be defined related to proposed coverage. Based on defined context variables, historical claim events are extracted from one or more sources of claims data. Extracted historical claim events may be representative of the proposed coverage. Historical claim events can be aggregated based on a time period to form aggregated claims data per time period. The aggregated data can then be used to determine a historical volatility time series based on differences between logarithms of the aggregated claims data per time period for a plurality of time periods. Additionally or alternately, the aggregated claims data per time period can be used to determine a fit of the aggregated data to one or more distributions. The fit can be evaluated, such as based on a fit parameter, to select a distribution. A calculation can then be performed to determine a premium. If a normal distribution is selected, the historical volatility time series can be used to estimate a volatility. This estimated volatility can then be used to calculate a premium.
Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on Real-Time 3-Dimensional Echocardiography (RT3DE) will be available to the physician at the time of implant. This location will be used as the target for optimal LV lead placement.